BAIO started only three months ago. But with a twice-a-week cadence and roughly five news stories in every issue, the numbers get big fast.
Readers who have been here from the beginning have now been served around 150 stories across protein design, virtual cells, AI agents, autonomous labs, clinical AI, drug delivery, foundation models, pharma deals, and everything else that now fits inside AI × bio.
And you start to see new things.
What I already knew when I started BAIO: Biology is both fast and slow. The tools are changing at absurd speed. But the thing we ultimately care about - helping people live longer, healthier lives - still has to pass through cells, animals, patients, regulators, manufacturing, safety, and time.
A molecule can be designed in minutes. A therapy still has to work in a body.
That is why AI × bio is such a strange field to cover. On one side, biology is brutally complex. Disease is often not like a software bug. Cells are not text. Human bodies do not care how impressive a benchmark looks.
On the other side, if we want any realistic shot at making biology more steerable - away from disease and toward health - we need artificial intelligence. Not as magic dust, and not as a replacement for validation, but as a way to search spaces too large for humans, spot patterns too subtle for us, and choose better experiments before the wet lab begins.
The prize is enormous. There is no bigger market than health, and no bigger human upside than fewer diseases, better medicines, and more time. That’s why I call it the tech story of the century.
So it is not surprising that the field is filling up fast. AI drug discovery companies are signing huge deals with pharma. Startups and research institutes are releasing tools, models, datasets, and papers almost daily. The largest AI companies are no longer circling the field from a distance. Google DeepMind and Isomorphic are already central. OpenAI is moving in. Anthropic is moving in. Amazon is moving in. Everyone wants a piece of the pie.
From the outside, that is the story: something big is happening.
Up close, the more interesting story is how.
Where are the real bottlenecks? Which parts of biology are now becoming measurable? Where do models actually help? Where do agents fail? What does validation really mean? Which companies are building the model, the lab, the dataset, the workflow, or the whole loop? And when AI solves one problem, what harder problem shows up next?
That is what these ten lessons are about.
My hope is that they make you a little wiser about where AI × bio actually is halfway through 2026 - and what to watch as the next layer of the field comes into view.